Study of Safety and Effect of T-AYU-HM Premium in Sickle Cell Anemia Patient: A Case Study

Sickle cell anaemia is a type of haemoglobin disorder causing morbidity and mortality in many countries. The disease incurable therefore requires symptomatic management to improve quality life. Because the alternative system medicine can play significant role life sickle anaemia, lot combinations formulations are attempted across Unfortunately, very few have reached preclinical clinical research level. In current case study, T-AYU-HM Premium was evaluated as per standard parameters, evaluation considering its effect safety performed this report 24-year-old male with history hereditary. History 8 times blood transfusion 7 hospitalization past two year. He infected covid-19 hospitalized, recovered only. Next month because joint pain, fever, weakness he visited daycare clinic. On complete physical laboratory examination started on 300mg tablets twice day. During 6 months treatment, had complained pain only thrice for which analgesics were prescribed, no required. period, there remarkable improvement his haemoglobin, red corpuscles, white cells, platelets. There untoward complaints from him suggesting that exhibited potential sustaining cellular integrity thereby preventing lysis corpuscles. parameters established studies indicated safe exhibit an observational corpuscles patient.